Results 111 to 120 of about 16,704 (236)
International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 931-941, September 2026.ABSTRACT Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are two highly prevalent airway diseases in the United States. While the coexistence of CRS and asthma is well recognized, less is known about the development of new‐onset asthma in CRS, particularly in the context of comorbid AR. This study assessed the impact of CRS and AR on
Austin J. Lee, Mohamad R. Chaaban
wiley +1 more source
Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS
International Forum of Allergy &Rhinology, Volume 16, Issue 9, Page 986-995, September 2026.ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion +11 more
wiley +1 more source
Role of TSLP in Dendritic Cell Programming during Allergic Responses
, 2016 Allergic diseases such as atopic dermatitis (AD), asthma and allergic rhinitis are among the most common chronic illnesses around the world. Although they cause significant discomfort to those affected, effective treatments are currently not available ...
Ochiai, Sotaro
core
, 2018 The thymic stromal lymphopoietin (TSLP)/TSLP receptor (TSLPR) axis is involved in multiple inflammatory immune diseases, including coronary artery disease (CAD).
Fan Wang (135182) +36 more
core +1 more source
Brain and Behavior, Volume 16, Issue 9, September 2026.In a Dermatophagoides farinae‐induced asthma model, IL‐31 deficiency did not substantially alter airway inflammation or immune responses but prevented the allergen‐induced enhancement of PAR‐2 expression and responsiveness in vagal sensory neurons.
Takayoshi Miyamoto +7 more
wiley +1 more source
Real‐World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis
Clinical and Translational Allergy, Volume 16, Issue 9, September 2026.ABSTRACT Background Tralokinumab, an interleukin‐13 (IL‐13) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate‐to‐severe atopic dermatitis (AD). This study aims to evaluate clinical and immunological outcome upon tralokinumab treatment in a real‐world cohort of patients with moderate‐to‐severe AD. Methods We recruited 81
Meslina Almaci +3 more
wiley +1 more source
Food Science &Nutrition, Volume 14, Issue 9, September 2026.Food‐derived bioactives, herbal extracts, and standardized botanical products are being investigated as adjunctive strategies for atopic dermatitis. Their biological activity is shaped not only by plant source and nominal dose, but also by fermentation, drying, heating, extraction, food‐matrix binding, gastrointestinal transformation, and formulation ...
Muhuang Zeng +3 more
wiley +1 more source
JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series
JEADV Clinical Practice, Volume 5, Issue 3, Page 951-955, September 2026.ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni +6 more
wiley +1 more source
Allergy, Volume 81, Issue 9, Page 3221-3235, September 2026.This study investigates the role of ER stress in steroid resistance in severe asthma. Results from advanced 3D models of human bronchial epithelial cells, steroid‐resistant severe asthma mouse models, and human severe asthma sputum samples show that treatment with ICS in combination with the ER stress inhibitor 4‐PBA significantly enhances steroid ...
Prabuddha S. Pathinayake +8 more
wiley +1 more source